Deals In Depth: May 2019
Executive Summary
As it plans to focus on core therapy areas following the Shire acquisition, Takeda divested dry eye drug Xiidra to Novartis for up to $5.3bn. 3M bought wound care firm Acelity from an investor consortium led by Apax partners for $6.7bn. Both pharma and device financing was up over the previous month, with strong showings from debt offerings.